FDA Approves Boehringer’s Stiolto Respimat For Chronic Obstructive Pulmonary Disease

Boehringer Ingelheim GmbH May 26 said that the Food and Drug Administration has approved once-daily Stiolto Respimat (tiotropium bromide and olodaterol) inhalation spray.

The product has been approved as a long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema, the company said. Stiolto Respimat isn’t indicated to treat asthma or acute deterioration of COPD and doesn’t replace the use of a rescue inhaler.

Tiotropium is a long-acting anticholinergic and the active ingredient in Spiriva Respimat and Spiriva HandiHaler, Boehringer Ingelheim said. Olodaterol, marketed as Striverdi Respimat, is a long-acting ...